Botulinum toxin is a neurotoxin produced by the bacteria Clostridium Botulinum that has several cosmetic and therapeutic uses. Botulinum toxin A, when injected, blocks the nerve signals that cause muscles to contract. Unlike BT, which is directly used to stop muscle movement, HA fillers are directly injected into the skin to fill wrinkles, depressed, or folded points in the face. It also brings water to the surface of the skin to keep it looking fresh and supple.
Botulinum Toxin and HA fillers are used for both aesthetic and therapeutic purposes. Both BT and HA fillers are generally used as non-surgical aesthetic injectables. The therapeutic uses of BT include procedures such as muscle movement disorders (cervical, dystonia, spasticity), urinary tract conditions (overactive bladder and urinary incontinence), excessive sweating, chronic migraine headache and others.
The global BT and HA fillers market is likely to grow strongly in the coming years driven by increasing female participation in employment, rising GDP per capita, increase in middle class population globally and ageing population. Key trends of the market include rising number of BT and HA filler procedures per surgeon, reduced safety concerns of aesthetic procedures and sustainable demand driven by short term procedure effect. However, growth of the market can be hindered by several factors including potential health risk of undergoing aesthetic procedures and intense competition leading to price fall.
Request To Get Sample Copy Of This Report: http://www.marketresearchreports.biz/sample/sample/922531
The report “Global Botulinum Toxin & HA fillers Market: Industry Analysis & Outlook (2017-2021)” by Koncept Analytics provides an extensive research and detailed analysis of the present market along with future outlook. The report discusses the major growth drivers and challenges of the market, covering the U.S., Europe and ROW regions along with the global market. The report profiles the key players of the market including Allergan, Medytox and Ipsen.